Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model

Executive Summary

NMEs and novel biologics will see reviews allotted two additional months under the revised model launching Oct. 1. Industry expects to gain more communication and first-cycle approvals, while FDA hopes it can receive more complete applications at submission and improve transparency.


Related Content

Want A Predicable Review For Your NDA? Use eCTD And Don't Amend It
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle
FDA May Require NDA Pre-Filing Meeting Under PDUFA V Review Model; Pilot Launching Soon
PDUFA V: FDA Application Completeness Crackdown Continues
What’s A "Complete" Application? Clarity From FDA Could Speed Review Times
PDUFA Talks: Four-Phase Review Flops; Automatic Extensions Back On Table
PDUFA Negotiations: FDA Wants To Be Able To Call "Time-Out" During Reviews
PDUFA Negotiations Focus On Review Delays; Firms, FDA See Different Causes
REMS Reform Looks To Be Theme Of PDUFA V: Stakeholders Call For Standardization, Earlier Notice
The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts